Physician profile
Ryan J Maybrook
NPI 1780856120
$10,487.30
in general payments reported to CMS, 2019-2025
46 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,375 · 2020: $983 · 2021: $1,156 · 2022: $1,334 · 2023: $1,850 · 2024: $2,079 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,518 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,518.27 |
| Education | $120.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,171.12 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $917.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $822.06 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Heartflow, INC. | $711.77 | 2023-2025 | Ffrct |
| Merck Sharp & Dohme LLC | $633.30 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $549.61 | 2019-2025 | Watchman Access System, Watchman |
| Sanofi-Aventis U.S. LLC | $510.66 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $484.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.72 | 2019-2025 | Jardiance |
| Cvrx, INC. | $296.33 | 2023-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $296.20 | 2022-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $287.10 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $277.85 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $274.40 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $270.79 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $219.30 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $181.99 | 2019-2021 | |
| Novo Nordisk INC | $177.03 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $167.20 | 2021-2022 | |
| Cleerly, INC. | $161.99 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Alnylam Pharmaceuticals INC. | $155.17 | 2023-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $105.93 | 2021-2025 | Nexletol |
| Biotronik INC. | $105.19 | 2019-2025 | Biomonitor |
| Bridgebio Pharma, INC. | $100.65 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $98.27 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $96.41 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $91.61 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $88.89 | 2022-2023 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $82.73 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Abiomed | $82.47 | 2024-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $72.91 | 2024 | Arcalyst |
| Abbott Laboratories | $72.09 | 2019-2023 | Jot Dx |
| Amarin Pharma, INC. | $71.45 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $60.85 | 2023-2024 | Assure Wcd |
| United Therapeutics Corporation | $54.59 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.79 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $51.57 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ionis Pharmaceuticals, INC. | $48.60 | 2025 | Tryngolza |
| Xeris Pharmaceuticals, INC. | $38.29 | 2023 | Keveyis |
| Daiichi Sankyo INC. | $24.19 | 2024 | Injectafer |
| Melinta Therapeutics, LLC | $16.75 | 2019 | |
| Medicure Pharma INC. | $16.18 | 2022 | |
| Bardy Diagnostics, INC. | $15.84 | 2022 | |
| Lilly USA, LLC | $14.16 | 2025 | Zepbound |
| G Medical Diagnostic Services, INC. | $14.16 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Maybrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.